Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

Sponsor

Inovio Pharmaceuticals (Industry)

Overall Status

Terminated

CT.gov ID

NCT00198315

Collaborator

(none)

130

Enrollment

Location

Arms

Duration (Months)

3.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the anterior oral cavity, soft palate, or tonsil.

Condition or Disease	Intervention/Treatment	Phase
Head and Neck Cancer	Combination Product: Medpulser electroporation with Bleomycin Procedure: Tumor surgical excision	Phase 3

Detailed Description

Recurrent tumors in head and neck squamous cell carcinoma usually have a poor prognosis. In patients suitable for salvage surgery of their recurrent disease, the success rate for local control has been reported to be 40-50%. The surgical treatment of H&N SCC frequently results in significant loss of organ function (e.g., inability to swallow, speak, etc.) and/or permanent disfigurement. There is a compelling and unmet medical need for a local therapy that destroys tumors while preserving function status and appearance in patients with primary, recurrent, or metastatic H&N SCC.

Comparison: To compare function status at 4 months after treatment with bleomycin-EPT or surgery in patients with locally recurrent or second primary SCC of the anterior oral cavity, soft palate, or tonsil that have failed primary curative therapy and in whom surgical resection is seen as an option for disease control.

Study Design

Study Type:

Interventional

Actual Enrollment :

130 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy

Study Start Date :

Jun 1, 2004

Actual Primary Completion Date :

Jun 1, 2007

Actual Study Completion Date :

Jun 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Surgery Control Patients will receive standard of care surgical removal of their tumor.	Procedure: Tumor surgical excision Patients have their tumor surgically removed.
Experimental: MedPulser EPT with Bleomycin Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.	Combination Product: Medpulser electroporation with Bleomycin Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.

Arm

Intervention/Treatment

Active Comparator: Surgery Control

Patients will receive standard of care surgical removal of their tumor.

Procedure: Tumor surgical excision

Patients have their tumor surgically removed.

Experimental: MedPulser EPT with Bleomycin

Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.

Combination Product: Medpulser electroporation with Bleomycin

Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.

Outcome Measures

Primary Outcome Measures

Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35) [4 Months]

Secondary Outcome Measures

Local tumor recurrence, disease free survival and overall survival rates through 2 years after bleomycin-EPT or surgery treatment [4 Months]
Safety through 6 months after the study treatment [6 Months]
Durability of function status outcomes at 8 months after bleomycin-EPT or surgery treatment [8 Months]
Pharmacoeconomic parameters through 8 months after bleomycin-EPT or surgery treatment [8 Months]
Bleomycin systemic absorption and plasma pharmacokinetics following intratracheal (IT) bleomycin-EPT administration [96 Hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The presence of SCC of the anterior oral cavity, soft palate or tonsil must be confirmed by histological examination of a tissue sample (e.g., biopsy) obtained within 1 month of the patient receiving the study treatment.
Recurrent or second primary disease in patients where surgical resection is seen as an option for disease control.
The length of the longest diameter of the study lesion must be < 5 cm and the calculated treatment volume must be < 60.0 cm3 (tumor volume plus a 0.5 cm margin around the tumor) for the study lesion [where treatment volume = 0.5 (A+1) (B+1)2 and where A = length of the longest diameter (cm), B = the next longest diameter perpendicular to "A" (cm)].
Tumor burden must be completely encompassed by surgery or bleomycin-EPT.
Age: 18 years or older.
Men and women of childbearing potential must use physician approved contraceptive methods for 7 days following bleomycin-EPT.
Hematopoietic status:

Absolute neutrophil count (ANC) > 1000/uL
Platelets > 75,000/mm3
Prothrombin time:international normalized ratio (PT:INR) ? 1.5 (correctable with vitamin K injection)

Blood chemistry status:

Transaminases < 3 times upper limit of normal
Total bilirubin < 2.5 mg/dL
Creatinine < 2.5 mg/dL

A written Informed Consent form must be signed prior to the patient receiving any study procedures or treatments.

Exclusion Criteria:

Patients with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
Patients with tumors having bone invasion.
Patients with any metallic implants in the treatment field.
Patients with hypersensitivity to bleomycin.
Patients who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.
Patients deemed unsuitable for general anesthesia.
Patients with a significant history of emphysema or pulmonary fibrosis.
Patients with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.
Patients with a history of uncontrolled cardiac arrhythmia.
Women who are pregnant, or are nursing. Women of childbearing potential must have a negative beta-human chorionic gonadotropin (beta-HCG) test within 7 days of study treatment.
Radiation therapy to the treatment area within 8 weeks of study treatment.
Chemotherapy or other cancer therapy (e.g., surgery, cryotherapy, etc.) to the treatment area within 4 weeks of study treatment.
Patients participating in a clinical study for an investigational drug or device within 4 weeks prior to the study treatment.
Patients previously randomized to this study.